新型GLP-1和胰高血糖素受体双激动剂在心血管安全性方面不劣于安慰剂
Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint
在SYNCHRONIZE-CVOT试验中,survodutide与安慰剂相比在主要心血管不良事件方面不劣于安慰剂,且治疗组在血压、体重、血糖等指标上有所改善。研究结果为该新型双激动剂的心血管安全性提供了数据支持。
研究证明新型GLP-1和胰高血糖素受体双激动剂在心血管安全性方面不劣于安慰剂,为临床应用提供了数据支持。
— Survodutide was noninferior to placebo for major adverse cardiovascular events, trial shows
by Susan Jeffrey, Contributing Writer, MedPage Today
November 11, 2026 • 3 min read
Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD, a randomized trial found.
Among more than 5,500 patients, the primary composite endpoint -- death from cardiovascular causes, nonfatal stroke, nonfatal myocardial infarction, ischemia-related coronary revascularization, or heart failure event -- occurred in 3.7% of those on survodutide versus 4.1% of those on placebo (P<0.0001 for noninferiority).
In the SYNCHRONIZE-CVOT trial, survodutide "met its primary endpoint, establishing cardiovascular safety by demonstrating noninferiority to placebo for MACE [major adverse cardiovascular events]," Biykem Bozkurt, MD, PhD, of Baylor College of Medicine in Houston, said during her presentation at the American Heart Association (AHA) annual meeting in Chicago.
This safety trial provides clinicians with "reassuring data" that treatment with the dual agonist is not associated with increased cardiovascular risk, Bozkurt and colleagues concluded in their report, published simultaneously in The Lancet.
"Given the novelty of this new incretin-based therapy class, establishing cardiovascular safety of glucagon receptor–GLP-1 receptor dual agonists through noninferiority trials is essential," the authors wrote, and has become an expectation by regulatory agencies both in the U.S. and Europe, Bozkurt added.
Treatment with survodutide was also associated with improvements in systolic blood pressure, waist circumference, HbA1C, body weight, lipid levels, and high-sensitivity C-reactive protein, Bozkurt said.
Gastrointestinal events and treatment discontinuations were more frequent during the dose escalation phase, she added. "Overall, the safety profile was consistent with that observed in the previously reported phase III trials with no unexpected safety findings," Bozkurt said.
AHA discussant Stephen Nicholls, MBBS, PhD, of Monash University in Melbourne, Australia, pointed out that the study design means that while cardiovascular harm can be excluded, "we cannot make any inference about cardiovascular benefit."
The findings raise the question of "what is important to stakeholders when we design our clinical trials?" Nicholls said. "From a regulatory perspective, it would seem it's a relatively low bar to simply show that there's no cardiovascular harm. We need to think more and more about how do we design clinical trials with what's important for our patients and the clinicians that they are working with."
The hope is to eventually triage the right patient to the right treatment at the right time in their disease process, Nicholls added, "and facilitate shared decision-making to achieve more effective personalized prevention of cardiovascular disease and obesity complications."
SYNCHRONIZE-CVOT was a global, phase III, randomized, double-blind, placebo-controlled, event-driven, cardiovascular safety trial conducted at 524 sites in 34 countries. Adult patients were eligible if they had a body mass index of 27 kg/m2 or greater, and established CVD or at least two obesity complications or CVD risk factors. Participants with CKD were eligible if they had a BMI of 30 kg/m2 or greater.
A total of 5,530 patients were randomly assigned to a once-weekly dose of subcutaneous survodutide, up-titrated to 3.6 mg or 6.0 mg, or placebo. Of these, 5,507 were actually treated, equally divided between the three dosing arms.
Median time in the study was 22 months. At study close-out, 56.0% of the survodutide 3.6-mg group, 56.6% of the survodutide 6.0-mg group, and 59.0% of the placebo group were still on treatment.
Efficacy and safety analyses included all randomly assigned patients who received at least one dose of survodutide or placebo. The primary analysis, which pooled outcomes for both survodutide doses compared with placebo, was performed according to the treatment-regimen estimand, which assessed treatment effects "regardless of any early discontinuation of survodutide or placebo, temporary stop, the use of protocol-prohibited obesity medications, or a prolonged dose-escalation period," the authors noted.
A secondary three-point MACE endpoint -- death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction -- occurred in 2.4% of 3,671 participants in the pooled survodutide group and 2.8% of 1,836 in the placebo group (P<0.0001 for non-inferiority).
Adverse events occurred in 93.0% of the 3.6-mg dose survodutide group, 93.1% of those in the 6.0-mg group, and 85.6% of those on placebo. Gastrointestinal events, including nausea and vomiting, were more frequent in the treated groups, and gastrointestinal events leading to discontinuation occurred in 19.3% of the 3.6-mg group, 20.8% of the 6.0-mg group, and 1.9% of the placebo group.
Serious adverse events and fatal adverse events were similar across treatment groups. Fatal events were primarily due to cardiac disorders, the authors noted.
来源:MedPage Today · medpagetoday.com